Quantum Biopharma Ltd. (NASDAQ:QNTM) Sees Large Decline in Short Interest

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totaling 180,859 shares, a decline of 27.1% from the March 31st total of 248,253 shares. Approximately 5.2% of the company’s shares are sold short. Based on an average daily trading volume, of 335,381 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Trading of Quantum Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QNTM. Virtu Financial LLC purchased a new stake in Quantum Biopharma in the fourth quarter valued at approximately $76,000. Jane Street Group LLC purchased a new stake in Quantum Biopharma in the fourth quarter valued at approximately $80,000. Finally, Platform Technology Partners purchased a new stake in Quantum Biopharma in the first quarter valued at approximately $199,000. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Quantum Biopharma Stock Up 1.4%

NASDAQ QNTM traded up $0.08 on Thursday, reaching $5.73. The stock had a trading volume of 485,475 shares, compared to its average volume of 322,750. The firm has a market capitalization of $21.89 million, a price-to-earnings ratio of -0.66 and a beta of 0.13. Quantum Biopharma has a 12-month low of $2.07 and a 12-month high of $38.25. The stock has a fifty day moving average price of $3.54 and a two-hundred day moving average price of $6.68.

Quantum Biopharma (NASDAQ:QNTM) last announced its earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49).

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wall Street Zen raised shares of Quantum Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.